STOCK TITAN

Jasper Therapeutics (JSPR) director details common and preferred stake

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Patrick J. Crutcher, a director of Jasper Therapeutics, Inc., directly holds 518,331.0000 shares of Voting Common Stock and Non-Voting Convertible Preferred Stock convertible into 463,452.0000 shares of Voting Common Stock. Each preferred share converts into 61 common shares after stockholder approval, subject to a 4.9%-19.9% beneficial ownership cap, and the preferred stock has no expiration date.

Positive

  • None.

Negative

  • None.
Insider Crutcher Patrick J
Role Director
Type Security Shares Price Value
holding Non-Voting Convertible Preferred Stock F1 -- -- --
holding Voting Common Stock -- -- --
Holdings After Transaction: Non-Voting Convertible Preferred Stock — 463,452 shares (Direct); Voting Common Stock — 518,331 shares (Direct)
Footnotes (1)
  1. F1. On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of Preferred Stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.
Voting Common Stock held 518331.0000 shares Directly held by director Patrick J. Crutcher following the reported holdings
Underlying shares from preferred 463452.0000 shares Voting Common Stock underlying Non-Voting Convertible Preferred Stock held directly
Conversion ratio 61 shares Each preferred share converts into 61 shares of Voting Common Stock after stockholder approval
Beneficial ownership cap range 4.9%-19.9% Holder-set limit on beneficial ownership of Voting Common Stock after conversion
Non-Voting Convertible Preferred Stock financial
"security title is "Non-Voting Convertible Preferred Stock" convertible into Voting Common Stock"
A non-voting convertible preferred stock is a share that normally pays a fixed dividend and takes priority over common stock for payouts, but does not grant the holder the right to vote on corporate matters. It can be exchanged later for a set number of common shares, offering the potential to participate in price gains without immediate control—like holding a high-yield loan that can be turned into equity, which matters to investors weighing steady income, upside potential, and possible dilution of ownership.
Voting Common Stock financial
"each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock"
beneficially own financial
"holder ... would beneficially own more than a specified percentage of the total number of shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
stockholder approval regulatory
"following the receipt of stockholder approval of the conversion of the preferred stock"
Stockholder approval is formal consent given by a company’s shareholders, usually through a vote at a meeting or by proxy, for major actions such as mergers, asset sales, changes to corporate structure, or amendments to governance rules. Investors pay attention because the vote can enable or block steps that materially change a company’s direction, ownership or value—like neighbors voting to allow a major renovation that would alter a building’s use and worth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What share holdings does Patrick J. Crutcher report in JSPR?

Patrick J. Crutcher reports 518,331.0000 shares of Voting Common Stock and Non-Voting Convertible Preferred Stock convertible into 463,452.0000 Voting Common Stock shares, all held directly. These figures reflect his reported equity stake as a director of Jasper Therapeutics, Inc.

How does the Non-Voting Convertible Preferred Stock in JSPR convert to common stock?

Each share of Non-Voting Convertible Preferred Stock automatically converts into 61 shares of Voting Common Stock on the third business day after stockholder approval of the conversion. This automatic conversion is also subject to a specified beneficial ownership limitation range.

What is the beneficial ownership limit on JSPR preferred stock conversion?

Conversion is limited so the holder cannot beneficially own more than a specified percentage of Voting Common Stock, set between 4.9% and 19.9%. This cap applies immediately after giving effect to any preferred stock conversion into Voting Common Stock.

Does the Non-Voting Convertible Preferred Stock of JSPR have an expiration date?

The Non-Voting Convertible Preferred Stock has no expiration date. It remains outstanding until converted into Voting Common Stock under the specified terms, including stockholder approval and compliance with the beneficial ownership percentage limitation.

Does Patrick J. Crutcher’s JSPR Form 3 show any recent share purchases or sales?

The reported positions reflect holdings only, with no purchases or sales indicated. The data show two holding entries and zero buy, sell, exercise, gift, or tax-withholding transactions for Jasper Therapeutics, Inc. securities in this report.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Crutcher Patrick J

(Last)(First)(Middle)
C/O JASPER THERAPEUTICS, INC.
2200 BRIDGE PKWY, SUITE #102

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
07/16/2026
3. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Voting Common Stock518,331D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Voting Convertible Preferred Stock (1) (1)Voting Common Stock463,452(1)D
Explanation of Responses:
1. On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of Preferred Stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.
/s/ Patrick J. Crutcher07/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)